Activated and inactivated PPARs-γ modulate experimentally induced colitis in rats

Medical Science Monitor

Volumn 17, Issue 4, 2011, Pages 116-124

  Celiński, Krzysztof ^a   Dworzański, Tomasz ^a   Korolczuk, Agnieszka ^a   SŁomka, Maria ^a   Radej, Sebastian ^a   Cichoz Lach, Halina ^a   Ma̧dro, Agnieszka ^a  

^a MEDICAL UNIVERSITY OF LUBLIN   (Poland)

Author keywords

BADGE; IL 10; IL 6; PPAR ; Rosiglitazone

Indexed keywords

2,2 BIS(4 GLYCIDYLOXYPHENYL)PROPANE; 2,4,6 TRINITROBENZENE SULFONIC ACID; INTERLEUKIN 10; INTERLEUKIN 6; MYELOPEROXIDASE; NITROBENZENE DERIVATIVE; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA; PEROXISOME PROLIFERATOR ACTIVATED RECEPTOR GAMMA ANTAGONIST; ROSIGLITAZONE; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; COLITIS; CONTROLLED STUDY; HISTOPATHOLOGY; IMMUNE RESPONSE; IMMUNOHISTOCHEMISTRY; INFLAMMATION; NEUTROPHIL; NONHUMAN; PROTEIN EXPRESSION; RAT; STOMACH TUBE;

ANIMALS; BODY WEIGHT; COLITIS; COLON; INTERLEUKIN-10; INTERLEUKIN-6; ORGAN SIZE; PEROXIDASE; PPAR GAMMA; RATS; RATS, WISTAR; TISSUE EXTRACTS;

EID: 79953718349     PISSN: 12341010     EISSN: 16433750     Source Type: Journal    
DOI: None     Document Type: Article

References (57)

1. Sokołowska M, Kowalski ML, Pawliczak R: Peroxisome proliferator-activated receptors-gamma (PPAR-gamma) and their role in immunoregulation and inflammation control. Postepy Hig Med Dosw, 2005; 59: 472-84
2. Celiński K, Dworzański T, Prozorow-Król B, Korolczuk A: The role of PPAR-g receptors in gastrointestinal inflammation diseases. Gastroenterol Pol, 2009; 16(1): 51-56
3. Celiński K, Ma{ogonek}dro A, Prozorow-Król B et al: Rosiglitazone, a peroxisome proliferator-activated receptor gamma (PPAR-g)-specific agonist, as a modulator in experimental acute pancreatitis. Med Sci Monit, 2009; 15(1): BR21-29
4. Stulc T, Ceska R: rosiglitazone in the prevention of diabetes and cardiovascular disease: dream or reality? Med Sci Monit, 2008; 14(4): RA45-47
5. Giaginis C, Katsamangou E, Tsourouflis G et al: Peroxisome proliferator-activated receptor-gamma and retinoid X receptor-alpha expression in pancreatic ductal adenocarcinoma: association with clinicopathological parameters, tumor proliferative capacity, and patients' survival. Med Sci Monit, 2009; 15(5): BR148-56
6. Chawla A, Schwarz EJ, Dimaculangan DD, Lazer MA: Peroxisome proliferator-activated receptor (PPAR) gamma: adipose-predominant expression and induction early in adipocyte differentiation. Endocrinology, 1994; 135(2): 798-800
7. Brun RP, Tontonoz P, Forman BM et al: Differential activation of adipogenesis by multiple PPAR isoforms. Genes Dev, 1996; 10(8): 974-84
8. Okuno A, Tamemoto H, Tobe K et al: Troglitazone increases the number of small adipocytes without the change of white adipose tissue mass in obese Zucker rats. J Clin Invest, 1998; 101(6): 1354-61
9. Chinetti G, Fruchart JC, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res, 2000; 49(10): 497-505
10. Debril MB, Renaud JP, Fajas L, Auwerx J: The pleiotropic functions of peroxisome proliferator-activated receptor gamma. J Mol Med, 2001; 79(1): 30-47
11. Li AC, Binder CJ, Gutierrez A et al: Differential inhibition of macrophage foam-cell formation and atherosclerosis in mice by PPARalpha, beta/delta, and gamma. J Clin Invest, 2004; 114(11): 1564-76
12. Chawla A, Barak Y, Nagy L et al: PPAR-gamma dependent and independent effects on macrophage-gene expression in lipid metabolism and inflammation. Nat Med, 2001; 7(1): 48-52
13. Greene ME, Blumberg B, McBride OW et al: Isolation of the human peroxisome proliferator activated receptor gamma cDNA: expression in hematopoietic cells and chromosomal mapping. Gene Expr, 1995; 4(4-5): 281-99
14. Ricote M, Huang JT, Welch JS, Glass CK: The peroxisome proliferatoractivated receptor(PPARgamma) as a regulator of monocyte/macrophage function. J Leukoc Biol, 1999; 66(5): 733-39
15. Tontonoz P, Nagy L, Alvarez JG et al: PPARgamma promotes monocyte/ macrophage differentiation and uptake of oxidized LDL. Cell, 1998; 93(2): 241-52
16. Konturek PC, Dembinski A, Warzecha Z et al: Pioglitazone, a specific ligand of peroxisome proliferator-activated receptor-gamma, protects pancreas against acute cerulein-induced pancreatitis. World J Gastroenterol, 2005; 11(40): 6322-29
17. Konturek PC, Brzozowski T, Engel M et al: Ghrelin ameliorates colonic inflammation. Role of nitric oxide and sensory nerves. J Physiol Pharmacol, 2009; 60(2): 41-47
18. Kieć-Wilk B, Dembińska-Kieć A, Olszanecka A et al: The selected pathophysiological aspects of PPARs activation. J Physiol Pharmacol, 2005; 56(2): 149-62
19. Ptak-Belowska A, Pawlik MW, Krzysiek-Maczka G et al: Transcriptional upregulation of gastrin in response to peroxisome proliferator-activated receptor gamma agonist triggers cell survival pathways. J Physiol Pharmacol, 2007; 58(4): 793-801
20. Fajas L, Auboeuf D, Raspe E et al: The organization, promotor analysis and exspression of the human PPAR gamma gen. J Biol Chem, 1997; 272: 18779-89
21. Elbrecht MJ, Chen Y, Cullian CA et al: Molecular cloning, expression and characterization of human peroxisome proliferators activated receptors gamma 1 and gamma 2. Biochem Biophys Res Commun, 1996; 224: 431-37
22. Vidal-Puig A, Jimenez-Liñan M, Lowell BB et al: Regulation of PPAR gamma gene expression by nutrition and obesity in rodents. J Clin Invest, 1996; 97(11): 2553-61
23. Lambe KG, Tugwood JD: A human peroxisome proliferators-activated receptor gamma is activated by inducers of adipogenesis including thiazolidedinedione drugs. Eur J Biochem, 1996; 239: 1-7
24. Pontsler AV, St Hilaire A, Marathe GK et al: Cyclooxygenase-2 is induced in monocytes by peroxisome proliferator activated receptor gamma and oxidized alkyl phospholipids from oxidized low density lipoprotein. J Biol Chem, 2002; 277(15): 13029-36
25. Thieringer R, Fenyk-Melody JE, Le Grand CB et al: Activation of peroxisome proliferator-activated receptor gamma does not inhibit IL-6 or TNF-alpha responses of macrophages to lipopolysaccharide in vitro or in vivo. J Immunol, 2000; 164(2): 1046-54
26. Asada K, Sasaki S, Suda T et al: Antiinflammatory roles of peroxisome proliferator-activated receptor gamma in human alveolar macrophages. Am J Respir Crit Care Med, 2004; 169(2): 195-200
27. Chinetti G, Fruchart J. C, Staels B: Peroxisome proliferator-activated receptors (PPARs): nuclear receptors at the crossroads between lipid metabolism and inflammation. Inflamm Res, 2000; 49(10): 497-505
28. Chinetti G, Lestavel S, Fruchart JC et al: Peroxisome proliferator-activated receptor alpha reduces cholesterol esterification in macrophages. Circ Res, 2003; 92(2): 212-17
29. Wang AC, Dai X, Luu B, Conrad DJ: Peroxisome proliferator-activated receptor-gamma regulates airway epithelial cell activation. Am J Respir Cell Mol Biol, 2001; 24(6): 688-93
30. Ricote M, Li AC, Willson TM et al: The peroxisome proliferators-activated receptor-gamma is a negative regulator of macrophage activation. Nature, 1998; 391: 79-82
31. Welch JS, Ricote M, Akiyama TE et al: PPARgamma and PPARdelta negatively regulate specific subsets of lipopolysaccharide and IFN-gamma target genes in macrophages. Proc Natl Acad Sci USA, 2003; 100(11): 6712-17
32. Jiang JG, Ting AT, Seed B: PPAR-gamma agonist inhibit production of monocyte inflammatory cytokines. Nature, 1998; 391: 82-86
33. Nawa T, Nawa MT, Cai Y et al: Repression of TNF-alpha-induced E-selectin expression by PPAR activators: involvement of transcriptional repressor LRF-1/ATF3. Biochem Biophys Res Commun, 2000; 275(2): 406-11
34. Yang XY, Wang LH, Chen T et al: Activation of human T lymphocytes is inhibited by peroxisome proliferator-activated receptor gamma (PPARgamma) agonists. PPARgamma co-association with transcription factor NFAT. J Biol Chem, 2000; 275(7): 4541-44
35. Clark RB, Bishop-Bailey D, Estrada-Hernandez T et al: The nuclear receptor PPAR gamma and immunoregulation: PPAR gamma mediates inhibition of helper T cell responses. J Immunol, 2000; 164(3): 1364-71
36. Padilla J, Kaur K, Cao HJ et al: Peroxisome proliferator activator receptor-gamma agonists and 15-deoxy Delta(12,14)(12,14)-PGJ(2) induce apoptosis in normal and malignant B-lineage cells. J Immunol, 2000; 165(12): 6941-48
37. Padilla J, Kaur K, Harris SG, Phipps RP: PPAR-gamma-mediated regulation of normal and malignant B lineage cells. Ann NY Acad Sci, 2000; 905: 97-109
38. Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón de la Lastra C: Rosiglitazone, a PPARg ligand, modulates signal transduction pathways during the development of acute TNBS-induced colitis in rats. Eur J Pharmacol, 2007; 562: 247-58
39. Sánchez-Hidalgo M, Martín AR, Villegas I, Alarcón de la Lastra C: Rosiglitazone, an agonist of peroxisome proliferator-activated receptor gamma, reduces chronic colonic inflammation in rats. Biochem Pharmacol, 2005; 69(12): 1733-44
40. Adachi M, Kurotani R, Morimura K et al: Peroxisome proliferator activated receptor gamma in colonic epithelial cells protects against experimental inflammatory bowel disease. Gut, 2006; 55(8): 1104-13
41. Lewis JD, Lichtenstein GR, Deren JJ et al: Rosiglitazone for active ulcerative colitis: a randomized placebo-controlled trial.; rosiglitazone for Ulcerative Colitis Study Group. Gastroenterology, 2008; 134(3): 688-95
42. Wright H, Clish C, Mikamii T et al: A Synthetic Antagonist for the Peroxisome Proliferator-activated Receptor g Inhibits Adipocyte Differentiation. J Biol Chem. 2000; 275(3): 1873-77
43. Poole A, van Herwijnen P, Weideli H et al: Review of the toxicology, human exposure and safety assessment for bisphenol A diglycidylether (BADGE). Food Addit Contam, 2004; 21(9): 905-19
44. Cabado AG, Aldea S, Porro C et al: Migration of BADGE (bisphenol A diglycidyl-ether) and BFDGE (bisphenol F diglycidyl-ether) in canned seafood. Food Chem Toxicol, 2008; 46(5): 1674-80
45. Takaki K, Mitsuyama K, Tsuruta O et al: Attenuation of experimental colonic injury by thiazolidinedione agents. Inflamm Res, 2006; 55(1): 10-15
46. Tanaka T, Kohno H, Yoshitani S et al: Ligands for peroxisome proliferator-activated receptors alpha and gamma inhibit chemically induced colitis and formation of aberrant crypt foci in rats. Cancer Res, 2001; 61(6): 2424-28
47. Ramakers JD, Verstege MI, Thuijls G et al: The PPARgamma agonist rosiglitazone impairs colonic inflammation in mice with experimental colitis. J Clin Immunol, 2007; 27(3): 275-83
48. Goła{ogonek}b J, Jakóbisiak M, Lasek W, Stokłosa T: Immunologia. 2007; 118-20
49. Noguchi D, Wakita D, Tajima M et al: Blocking of IL-6 signaling pathway prevents CD4+ T cell-mediated colitis in a T(h)17-independent manner. Int Immunol, 2007; 19(12): 1431-40
50. Yamamoto K, Ninomiya Y, Iseki M et al: 4-Hydroxydocosahexaenoic acid, a potent peroxisome proliferator-activated receptor c agonist alleviates the symptoms of DSS-induced colitis. Biochem Biophys Res Commun, 2008; 367: 566-72
51. Matharu KS, Mizoguchi E, Cotoner CA et al: Toll-like receptor 4-mediated regulation of spontaneous Helicobacter-dependent colitis in IL-10-deficient mice. Gastroenterology, 2009; 137(4): 1380-90
52. Goła{ogonek}b J, Jakóbisiak M, Lasek W, Stokłosa T: Immunologia, 2007; 121-23
53. Lytle C, Tod BS, Kathy T et al: The Peroxisome Proliferator-Activated Receptor g Ligand rosiglitazone Delays the Onset of Inflammatory Bowel Disease in Mice with Interleukin 10 Deficiency. Inflamm Bowel Dis, 2005; 11: 231-43
54. Saubermann LJ, Nakajima A, Wada K et al: Peroxisome proliferatoractivated receptor gamma agonist ligands stimulate a Th2 cytokine response and prevent acute colitis. Inflamm Bowel Dis, 2002; 8(5): 330-39
55. Van Schooten FJ, Boots AW, Knaapen AM et al: Myeloperoxidase (MPO)-463G->A reduces MPO activity and DNA adduct levels in bronchoalveolar lavages of smokers. Cancer Epidemiol Biomarkers Prev, 2004; 13(5): 828-33
56. Zhang AH, Chen M, Gao Y et al: Inhibition of oxidation activity of myeloperoxidase (MPO) by propylthiouracil (PTU) and anti-MPO antibodies from patients with PTU-induced vasculitis. Clin Immunol, 2007; 122(2): 187-93
57. Cuzzocrea S, Di Paola R, Mazzon E et al: Role of endogenous and exogenous ligands for the peroxisome proliferators activated receptors alpha (PPAR-a) in the development of inflammatory bowel disease in mice. Lab Invest, 2004; 84: 1643-54